By Fineline Cube 
China-based Jiangsu Recbio Technology Co., Ltd. (HKG: 2179) announced a licensing agreement with India-headquartered Biological E. The deal centers on Recbio’s recombinant 9-valent human papillomavirus (HPV) vaccine REC603, targeting individuals aged 9 to 45. The vaccine is currently in the key visitation phase of Phase III clinical trials in China.
Collaboration Details
Under the agreement, Biological E secures exclusive rights to develop, manufacture, and commercialize REC603 in India and in tender markets led by UNICEF and the Pan American Health Organization (PAHO). Recbio has already received an upfront payment and will receive milestone payments based on collaboration progress, along with royalties linked to a percentage of annual net sales.
Biological E’s Background
Founded in 1953, Biological E is India’s first private-sector biopharmaceutical company, with extensive expertise in vaccine R&D, production, and commercialization. It is a key partner of UNICEF and PAHO. Its portfolio includes 10 WHO-prequalified vaccines and 10 USFDA-approved generic injectables.-Fineline Info & Tech